215 related articles for article (PubMed ID: 19356388)
1. Pharmacist intervention in activated protein C therapy for severe sepsis: influence on health and economic outcomes.
Chan AL; Hsieh HJ; Lin SJ
Int J Clin Pharmacol Ther; 2009 Apr; 47(4):229-35. PubMed ID: 19356388
[TBL] [Abstract][Full Text] [Related]
2. Timing of drotrecogin alfa (activated) initiation in treatment of severe sepsis: a database cohort study of hospital mortality, length of stay, and costs.
Ernst FR; Johnston JA; Pulgar S; He J; Ball DE; Young JK; Cooper LM
Curr Med Res Opin; 2007 Jan; 23(1):235-44. PubMed ID: 17207305
[TBL] [Abstract][Full Text] [Related]
3. Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial.
Laterre PF; Levy H; Clermont G; Ball DE; Garg R; Nelson DR; Dhainaut JF; Angus DC
Crit Care Med; 2004 Nov; 32(11):2207-18. PubMed ID: 15640632
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis.
Angus DC; Linde-Zwirble WT; Clermont G; Ball DE; Basson BR; Ely EW; Laterre PF; Vincent JL; Bernard G; van Hout B;
Crit Care Med; 2003 Jan; 31(1):1-11. PubMed ID: 12544986
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom.
Davies A; Ridley S; Hutton J; Chinn C; Barber B; Angus DC
Anaesthesia; 2005 Feb; 60(2):155-62. PubMed ID: 15644013
[TBL] [Abstract][Full Text] [Related]
6. [Cost-effectiveness of drotrecogin alpha [activated] in the treatment of severe sepsis in Spain].
Sacristán JA; Prieto L; Huete T; Artigas A; Badia X; Chinn C; Hudson P
Gac Sanit; 2004; 18(1):50-7. PubMed ID: 14980173
[TBL] [Abstract][Full Text] [Related]
7. Drotrecogin alfa (activated): a pharmacoeconomic review of its use in severe sepsis.
Frampton JE; Foster RH
Pharmacoeconomics; 2004; 22(7):445-76. PubMed ID: 15137883
[TBL] [Abstract][Full Text] [Related]
8. Drotrecogin alfa (activated) for severe sepsis.
Drug Ther Bull; 2006 Jan; 44(1):5-8. PubMed ID: 16425899
[TBL] [Abstract][Full Text] [Related]
9. Assessing the effect of the Surviving Sepsis Campaign treatment guidelines on clinical outcomes in a community hospital.
Patel GW; Roderman N; Gehring H; Saad J; Bartek W
Ann Pharmacother; 2010 Nov; 44(11):1733-8. PubMed ID: 20978215
[TBL] [Abstract][Full Text] [Related]
10. Management challenge with drotrecogin alfa (activated).
Vanscoy GJ
Am J Health Syst Pharm; 2002 Feb; 59 Suppl 1():S23-9. PubMed ID: 11885411
[TBL] [Abstract][Full Text] [Related]
11. Clinical response to unintentionally rapid infusion of drotrecogin alfa (activated).
Urban TM; Mitchell GA; Wellborn-Kim JJ; Terneus WF; Callahan CM; Mendes J; Webber SL
Am J Health Syst Pharm; 2010 Jul; 67(14):1174-7. PubMed ID: 20592322
[TBL] [Abstract][Full Text] [Related]
12. Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis.
Bernard GR; Margolis BD; Shanies HM; Ely EW; Wheeler AP; Levy H; Wong K; Wright TJ;
Chest; 2004 Jun; 125(6):2206-16. PubMed ID: 15189943
[TBL] [Abstract][Full Text] [Related]
13. Drotrecogin alfa (activated): diffusion from clinical trials to clinical practice.
Ridley S; Lwin A; Wyncoll D; Lippett S; Watson D; Gunning K; Higgins D
Eur J Anaesthesiol; 2008 Mar; 25(3):211-6. PubMed ID: 18031590
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany.
Neilson AR; Burchardi H; Chinn C; Clouth J; Schneider H; Angus D
J Crit Care; 2003 Dec; 18(4):217-27. PubMed ID: 14691895
[TBL] [Abstract][Full Text] [Related]
15. Drotrecogin alfa (activated) for severe sepsis: could we consider a shorter treatment period in patients with a favorable course?
Ahishakiye D; Lorent S; De Backer D; Gottignies P; Vincent JL
J Crit Care; 2009 Dec; 24(4):590-4. PubMed ID: 19577419
[TBL] [Abstract][Full Text] [Related]
16. An evaluation of the cost effectiveness of drotrecogin alfa (activated) relative to the number of organ system failures.
Betancourt M; McKinnon PS; Massanari RM; Kanji S; Bach D; Devlin JW
Pharmacoeconomics; 2003; 21(18):1331-40. PubMed ID: 14750900
[TBL] [Abstract][Full Text] [Related]
17. Evidence-based disease management in medication-use evaluation: application to drotrecogin alfa (activated) in severe sepsis.
Durthaler JM; Ernst FR
Am J Health Syst Pharm; 2006 Aug; 63(15):1453-60. PubMed ID: 16849712
[No Abstract] [Full Text] [Related]
18. Survival analysis of 314 episodes of sepsis in medical intensive care unit in university hospital: impact of intensive care unit performance and antimicrobial therapy.
Degoricija V; Sharma M; Legac A; Gradiser M; Sefer S; Vucicević Z
Croat Med J; 2006 Jun; 47(3):385-97. PubMed ID: 16758516
[TBL] [Abstract][Full Text] [Related]
19. 90-day follow-up of patients treated with Drotrecogin Alfa (activated) for severe sepsis: a Belgian open label study.
Decruyenaere J; De Backer D; Spapen H; Laterre PF; Raemaekers J; Rogiers P; Trine H; Sartral M; Haentjens T; Wagner T
Acta Clin Belg; 2009; 64(1):16-22. PubMed ID: 19317237
[TBL] [Abstract][Full Text] [Related]
20. Filter survival time and requirement of blood products in patients with severe sepsis receiving drotrecogin alfa (activated) and requiring renal replacement therapy.
Camporota L; Corno E; Menaldo E; Smith J; Lei K; Beale R; Wyncoll D
Crit Care; 2008; 12(6):R163. PubMed ID: 19094233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
